ERBB2 and breast neoplasm: Among 105 advanced-stage patients with HER2-negative breast tumours and high-risk HER2-positive CTC, those who received anti-HER2 targeted therapies had improved PFS compared to those who did not; however, anti-HER2 targeted therapy did not affect PFS in patients with low-risk CTC HER2 [33].